RESUMO
AIMS: Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a life-threatening condition often associated with highly raised serum antibodies to glycine receptors (GlyRs); these bind to the surface of large neurons and interneurons in rodent brain and spinal cord sections and, in vitro, inhibit function and reduce surface expression of the GlyRs. The effects in vivo have not been reported. METHODS: Purified plasma IgG from a GlyR antibody-positive patient with PERM, and a healthy control (HC), was injected daily into the peritoneal cavity of mice for 12 days; lipopolysaccharide (LPS) to open the blood-brain barrier, was injected on days 3 and 8. Based on preliminary data, behavioural tests were only performed 48 h post-LPS on days 5-7 and 10-12. RESULTS: The GlyR IgG injected mice showed impaired ability on the rotarod from days 5 to 10 but this normalized by day 12. There were no other behavioural differences but, at termination (d13), the GlyR IgG-injected mice had IgG deposits on the neurons that express GlyRs in the brainstem and spinal cord. The IgG was not only on the surface but also inside these large GlyR expressing neurons, which continued to express surface GlyR. CONCLUSIONS: Despite the partial clinical phenotype, not uncommon in passive transfer studies, the results suggest that the antibodies had accessed the GlyRs in relevant brain regions, led to antibody-mediated internalization and increased GlyR synthesis, compatible with the temporary loss of function.
Assuntos
Autoanticorpos/farmacologia , Encefalomielite/imunologia , Imunoglobulina G/farmacologia , Neurônios Motores/metabolismo , Rigidez Muscular/imunologia , Receptores de Glicina/metabolismo , Animais , Autoanticorpos/imunologia , Autoantígenos/imunologia , Autoantígenos/metabolismo , Tronco Encefálico/imunologia , Tronco Encefálico/metabolismo , Encefalomielite/metabolismo , Humanos , Imunoglobulina G/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurônios Motores/imunologia , Rigidez Muscular/metabolismo , Mioclonia/imunologia , Mioclonia/metabolismo , Receptores de Glicina/imunologia , Medula Espinal/imunologia , Medula Espinal/metabolismoRESUMO
OBJECTIVE: Impairment of glycinergic neurotransmission leads to complex movement and behavioral disorders. Patients harboring glycine receptor autoantibodies suffer from stiff-person syndrome or its severe variant progressive encephalomyelitis with rigidity and myoclonus. Enhanced receptor internalization was proposed as the common molecular mechanism upon autoantibody binding. Although functional impairment of glycine receptors following autoantibody binding has recently been investigated, it is still incompletely understood. METHODS: A cell-based assay was used for positive sample evaluation. Glycine receptor function was assessed by electrophysiological recordings and radioligand binding assays. The in vivo passive transfer of patient autoantibodies was done using the zebrafish animal model. RESULTS: Glycine receptor function as assessed by glycine dose-response curves showed significantly decreased glycine potency in the presence of patient sera. Upon binding of autoantibodies from 2 patients, a decreased fraction of desensitized receptors was observed, whereas closing of the ion channel remained fast. The glycine receptor N-terminal residues 29 A to 62 G were mapped as a common epitope of glycine receptor autoantibodies. An in vivo transfer into the zebrafish animal model generated a phenotype with disturbed escape behavior accompanied by a reduced number of glycine receptor clusters in the spinal cord of affected animals. INTERPRETATION: Autoantibodies against the extracellular domain mediate alterations of glycine receptor physiology. Moreover, our in vivo data demonstrate that the autoantibodies are a direct cause of the disease, because the transfer of human glycine receptor autoantibodies to zebrafish larvae generated impaired escape behavior in the animal model compatible with abnormal startle response in stiff-person syndrome or progressive encephalitis with rigidity and myoclonus patients. ANN NEUROL 2020;88:544-561.
Assuntos
Autoanticorpos/imunologia , Encefalomielite/imunologia , Rigidez Muscular/imunologia , Receptores de Glicina/metabolismo , Rigidez Muscular Espasmódica/imunologia , Adulto , Idoso , Animais , Autoanticorpos/farmacologia , Autoantígenos/imunologia , Comportamento Animal/efeitos dos fármacos , Encefalomielite/metabolismo , Epitopos de Linfócito B/imunologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Rigidez Muscular/metabolismo , Receptores de Glicina/imunologia , Rigidez Muscular Espasmódica/metabolismo , Peixe-ZebraRESUMO
BACKGROUND AND PURPOSE: Antibodies to glycine receptors (GlyR-Abs) were first defined in progressive encephalopathy with rigidity and myoclonus (PERM) but were subsequently identified in other clinical presentations. Our aim was to assess the clinical associations of all patients identified with GlyR-Abs in Queensland, Australia, between April 2014 and May 2017 and to compare these to cases reported in the literature. METHODS: A literature review identified the clinical features of all published GlyR-Ab-positive cases through online databases. A case series was undertaken via collection of clinical information from all patients diagnosed or known to immunology, pathology or neurological services in Queensland during the study period of 3 years. RESULTS: In all, 187 GlyR-Ab-positive cases were identified in the literature. The majority (47.6%) had PERM, 22.4% had epilepsy, but the remaining 30% included mixed phenotypes consisting of cerebellar ataxia, movement disorders, demyelination and encephalitis/cognitive dysfunction. By contrast, in our series of 14 cases, eight had clinical presentations consistent with seizures and epilepsy and only three cases had classical features of PERM. There was one case each of global fatiguable weakness with sustained clonus, laryngeal dystonia and movement disorder with hemiballismus and tics. The rate of response to immune therapy was similar in all groups. CONCLUSION: Antibodies to glycine receptors are linked to a spectrum of neurological disease. The results of the literature review and our case series suggest a greater relationship between GlyR-Abs and epilepsy than previously reported.
Assuntos
Autoanticorpos , Rigidez Muscular/imunologia , Mioclonia/imunologia , Receptores de Glicina/imunologia , Adolescente , Adulto , Idoso , Austrália , Criança , Pré-Escolar , Encefalite/imunologia , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Transtornos dos Movimentos/imunologia , Fenótipo , Adulto JovemRESUMO
The identification of new variants of the stiff man syndrome (SMS) and of new, probably pathogenic neuronal autoantibodies has led to the concept of stiff man (or person) spectrum disorders (SPSD). This is an expanding group of rare chronic autoimmune inflammatory diseases of the central nervous system (CNS) that have in common the main symptoms of fluctuating rigidity and spasms with pronounced stimulus sensitivity. These core symptoms are mandatory and can be accompanied by a wide variety of other neurological signs. The SPSDs are associated with autoantibodies directed against neuronal proteins that attenuate excitability. Neither clinical phenotypes nor the course of SPSD correlate closely with the antibody status. The treatment of these diseases aims at maintaining mobility and is pragmatically oriented to the degree of impediment and comprises antispastic, anticonvulsant and immunomodulating or immunosuppressive medication strategies.
Assuntos
Rigidez Muscular Espasmódica/diagnóstico , Autoanticorpos/sangue , Doenças Autoimunes/classificação , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/imunologia , Doenças Autoimunes/terapia , Sistema Nervoso Central/imunologia , Correlação de Dados , Diagnóstico Diferencial , Encefalomielite/classificação , Encefalomielite/diagnóstico , Encefalomielite/imunologia , Encefalomielite/terapia , Humanos , Rigidez Muscular/classificação , Rigidez Muscular/diagnóstico , Rigidez Muscular/imunologia , Rigidez Muscular/terapia , Proteínas do Tecido Nervoso/imunologia , Prognóstico , Qualidade de Vida , Rigidez Muscular Espasmódica/classificação , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/terapiaRESUMO
PURPOSE OF REVIEW: This review highlights the recent discovery of antibodies to glycine receptor (GlyR-Ab) and discusses the relationship between these antibodies and neurological disorders. RECENT FINDINGS: Since the initial description in 2008 of antibodies to glycine receptors (GlyR-Abs) in a patient with progressive encephalomyelitis with rigidity and myoclonus (PERM), these antibodies have been found in PERM and in some patients with a variety of stiff person spectrum (SPS) or related disorders. Patients with GlyR-Abs often improve with aggressive immunotherapy, and antibody titres correlate with disease severity. Around 25% of patients have another autoimmune condition and 10-20% have an underlying malignancy. GlyR-Abs bind to extracellular determinants, are mainly Immunoglobulin G1 subclass and induce GlyR internalization in Human embryonic kidney 293 cells, suggesting pathogenicity. The spectrum of neurological disease associated with GlyR-Abs has not been fully characterized, and lower titres may not be syndrome specific, but GlyR-Abs, like antibodies to other neuronal cell-surface antigens, define immunotherapy-responsive disease and are likely to be pathogenic. This distinguishes them from the glutamic acid decarboxylase antibodies that can also be found at high titres in patients with classical stiff person syndrome which is more often chronic and relatively resistant to immunological treatments. SUMMARY: Irrespective of the clinical features, GlyR-Abs are helpful in the diagnosis of patients who very often have a subacute, progressive and life-threatening disorder which shows a favourable response to immunotherapy.
Assuntos
Autoanticorpos/análise , Encefalomielite/imunologia , Rigidez Muscular/imunologia , Mioclonia/imunologia , Receptores de Glicina/imunologia , Encefalomielite/complicações , Encefalomielite/terapia , Humanos , Rigidez Muscular/etiologia , Rigidez Muscular/terapia , Mioclonia/etiologia , Mioclonia/terapia , Rigidez Muscular Espasmódica/imunologiaRESUMO
The clinical associations of glycine receptor antibodies have not yet been described fully. We identified prospectively 52 antibody-positive patients and collated their clinical features, investigations and immunotherapy responses. Serum glycine receptor antibody endpoint titres ranged from 1:20 to 1:60 000. In 11 paired samples, serum levels were higher than (n = 10) or equal to (n = 1) cerebrospinal fluid levels; there was intrathecal synthesis of glycine receptor antibodies in each of the six pairs available for detailed study. Four patients also had high glutamic acid decarboxylase antibodies (>1000 U/ml), and one had high voltage-gated potassium channel-complex antibody (2442 pM). Seven patients with very low titres (<1:50) and unknown or alternative diagnoses were excluded from further study. Three of the remaining 45 patients had newly-identified thymomas and one had a lymphoma. Thirty-three patients were classified as progressive encephalomyelitis with rigidity and myoclonus, and two as stiff person syndrome; five had a limbic encephalitis or epileptic encephalopathy, two had brainstem features mainly, two had demyelinating optic neuropathies and one had an unclear diagnosis. Four patients (9%) died during the acute disease, but most showed marked improvement with immunotherapies. At most recent follow-up, (2-7 years, median 3 years, since first antibody detection), the median modified Rankin scale scores (excluding the four deaths) decreased from 5 at maximal severity to 1 (P < 0.0001), but relapses have occurred in five patients and a proportion are on reducing steroids or other maintenance immunotherapies as well as symptomatic treatments. The glycine receptor antibodies activated complement on glycine receptor-transfected human embryonic kidney cells at room temperature, and caused internalization and lysosomal degradation of the glycine receptors at 37°C. Immunoglobulin G antibodies bound to rodent spinal cord and brainstem co-localizing with monoclonal antibodies to glycine receptor-α1. Ten glycine receptor antibody positive samples were also identified in a retrospective cohort of 56 patients with stiff person syndrome and related syndromes. Glycine receptor antibodies are strongly associated with spinal and brainstem disorders, and the majority of patients have progressive encephalomyelitis with rigidity and myoclonus. The antibodies demonstrate in vitro evidence of pathogenicity and the patients respond well to immunotherapies, contrasting with earlier studies of this syndrome, which indicated a poor prognosis. The presence of glycine receptor antibodies should help to identify a disease that responds to immunotherapies, but these treatments may need to be sustained, relapses can occur and maintenance immunosuppression may be required.
Assuntos
Anticorpos/sangue , Encefalomielite/imunologia , Rigidez Muscular/imunologia , Mioclonia/imunologia , Receptores de Glicina/imunologia , Rigidez Muscular Espasmódica/imunologia , Adolescente , Adulto , Idoso , Animais , Anticorpos/líquido cefalorraquidiano , Criança , Pré-Escolar , Comorbidade , Encefalomielite/tratamento farmacológico , Encefalomielite/epidemiologia , Encefalomielite/fisiopatologia , Epilepsias Mioclônicas/epidemiologia , Feminino , Glutamato Descarboxilase/imunologia , Células HEK293 , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Rigidez Muscular/tratamento farmacológico , Rigidez Muscular/epidemiologia , Rigidez Muscular/fisiopatologia , Mioclonia/tratamento farmacológico , Mioclonia/epidemiologia , Mioclonia/fisiopatologia , Neoplasias/epidemiologia , Avaliação de Resultados em Cuidados de Saúde , Canais de Potássio de Abertura Dependente da Tensão da Membrana/imunologia , Estudos Prospectivos , Ratos , Rigidez Muscular Espasmódica/tratamento farmacológico , Rigidez Muscular Espasmódica/epidemiologia , Rigidez Muscular Espasmódica/fisiopatologia , Síndrome , Adulto JovemAssuntos
Catatonia/diagnóstico , Encefalomielite/diagnóstico , Rigidez Muscular/diagnóstico , Mioclonia/diagnóstico , Autoanticorpos/imunologia , Doenças Autoimunes do Sistema Nervoso/diagnóstico , Doenças Autoimunes do Sistema Nervoso/imunologia , Diagnóstico Diferencial , Encefalomielite/complicações , Encefalomielite/imunologia , Feminino , Glutamato Descarboxilase/imunologia , Humanos , Deficiência Intelectual/complicações , Pessoa de Meia-Idade , Rigidez Muscular/complicações , Rigidez Muscular/imunologia , Mioclonia/complicações , Mioclonia/imunologia , SíndromeRESUMO
Background and objectives: Antiglycine receptor (anti-GlyR) antibody mediates multiple immune-related diseases. This study aimed to summarize the clinical features to enhance our understanding of anti-GlyR antibody-related disease. Methods: By collecting clinical information from admitted patients positive for glycine receptor (GlyR) antibody, the clinical characteristics of a new patient positive for GlyR antibody were reported in this study. To obtain additional information regarding anti-GlyR antibody-linked illness, clinical data and findings on both newly reported instances in this study and previously published cases were merged and analyzed. Results: A new case of anti-GlyR antibody-related progressive encephalomyelitis with rigidity and myoclonus (PERM) was identified in this study. A 20-year-old man with only positive cerebrospinal fluid anti-GlyR antibody had a good prognosis with first-line immunotherapy. The literature review indicated that the common clinical manifestations of anti-GlyR antibody-related disease included PERM or stiff-person syndrome (SPS) (n = 179, 50.1%), epileptic seizure (n = 94, 26.3%), and other neurological disorders (n = 84, 24.5%). Other neurological issues included demyelination, inflammation, cerebellar ataxia and movement disorders, encephalitis, acute psychosis, cognitive impairment or dementia, celiac disease, Parkinson's disease, neuropathic pain and allodynia, steroid-responsive deafness, hemiballism/tics, laryngeal dystonia, and generalized weakness included respiratory muscles. The group of PERM/SPS exhibited a better response to immunotherapy than others. Conclusions: The findings suggest the presence of multiple clinical phenotypes in anti-GlyR antibody-related disease. Common clinical phenotypes include PERM, SPS, epileptic seizure, and paraneoplastic disease. Patients with RERM/SPS respond well to immunotherapy.
Assuntos
Autoanticorpos , Encefalomielite , Rigidez Muscular , Receptores de Glicina , Humanos , Masculino , Receptores de Glicina/imunologia , Autoanticorpos/imunologia , Autoanticorpos/sangue , Adulto Jovem , Encefalomielite/imunologia , Encefalomielite/diagnóstico , Rigidez Muscular/imunologia , Rigidez Muscular/etiologia , Rigidez Muscular/diagnóstico , Mioclonia/imunologia , Mioclonia/diagnóstico , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/terapia , AdultoRESUMO
OBJECTIVE: Antibodies against glutamic acid decarboxylase (GAD), originally associated with stiff person syndrome (SPS), define the GAD antibody-spectrum disorders that also include cerebellar ataxia, autoimmune epilepsy, limbic encephalitis, progressive encephalomyelitis with rigidity and myoclonus (PERM), and eye movement disorders, all of which are characterized by autoimmune neuronal excitability. This article elaborates on the diagnostic criteria for SPS and SPS spectrum disorders, highlights disease mimics and misdiagnoses, describes the electrophysiologic mechanisms and underlying autoimmunity of stiffness and spasms, and provides a step-by-step therapeutic scheme. LATEST DEVELOPMENTS: Very-high serum GAD antibody titers are diagnostic for GAD antibody-spectrum disorders and also predict the presence of GAD antibodies in the CSF, increased intrathecal synthesis, and reduced CSF γ-aminobutyric acid (GABA) levels. Low serum GAD antibody titers or the absence of antibodies generates diagnostic challenges that require careful distinction in patients with a variety of painful spasms and stiffness, including functional neurologic disorders. Antibodies against glycine receptors, first found in patients with PERM, are seen in 13% to 15% of patients with SPS, whereas amphiphysin and gephyrin antibodies, seen in 5% of patients with SPS spectrum disorders, predict a paraneoplastic association. GAD-IgG from different SPS spectrum disorders recognizes the same dominant GAD intracellular epitope and, although the pathogenicity is unclear, is an excellent diagnostic marker. The biological basis of muscle stiffness and spasms is related to autoimmune neuronal hyperexcitability caused by impaired reciprocal γ-aminobutyric acid-mediated (GABA-ergic) inhibition, which explains the therapeutic response to GABA-enhancing agents and immunotherapies. ESSENTIAL POINTS: It is essential to distinguish SPS spectrum disorders from disease mimics to avoid both overdiagnoses and misdiagnoses, considering that SPS is treatable if managed correctly from the outset to prevent disease progression. A step-by-step, combination therapy of GABA-enhancing medications along with immunotherapies ensures prolonged clinical benefits.
Assuntos
Autoanticorpos , Glutamato Descarboxilase , Rigidez Muscular Espasmódica , Humanos , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/fisiopatologia , Rigidez Muscular Espasmódica/sangue , Glutamato Descarboxilase/imunologia , Autoanticorpos/sangue , Masculino , Feminino , Rigidez Muscular/diagnóstico , Rigidez Muscular/imunologia , Rigidez Muscular/tratamento farmacológico , Encefalomielite/diagnóstico , Encefalomielite/imunologia , Encefalomielite/sangue , Pessoa de Meia-Idade , Adulto , Ataxia Cerebelar/diagnóstico , Ataxia Cerebelar/imunologia , Ataxia Cerebelar/sangue , Ataxia Cerebelar/fisiopatologia , Encefalite Límbica/diagnóstico , Encefalite Límbica/imunologia , Encefalite Límbica/terapia , Encefalite Límbica/sangue , Encefalite Límbica/fisiopatologiaRESUMO
Stiff-person syndrome (SPS) usually manifests as an autoimmune neuromuscular disorder characterised by pronounced and advancing rigidity, primarily affecting the trunk and proximal muscles. There are various clinical subtypes like classic SPS (truncal stiffness, generalised rigidity and muscle spasms), partial SPS (stiff-limb syndrome) and uncommon forms including progressive encephalomyelitis with rigidity and myoclonus. Camptocormia, defined as forward flexion of the spine in the upright position that disappears in the supine position, without fixed deformity, has been described only in two cases as an initial presentation of Anti glutamic acid decarboxylase (GAD) autoimmunity. We encountered a young male presenting with a progressive forward-leaning posture and involuntary rhythmic movements in the lower limb. Diagnostic workup included MRI, blood routines, autoimmune screening, genetic testing, lumbar puncture and electromyography. Elevated serum anti-GAD antibody levels, inflammatory CSF and certain other clinical features supported the diagnosis of SPS. Treatment involved benzodiazepines, muscle relaxants and immunotherapy with intravenous immunoglobulin. This case underscores the importance of considering immune-mediated causes, such as SPS, in patients presenting with camptocormia.
Assuntos
Glutamato Descarboxilase , Atrofia Muscular Espinal , Curvaturas da Coluna Vertebral , Rigidez Muscular Espasmódica , Humanos , Masculino , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/complicações , Curvaturas da Coluna Vertebral/imunologia , Curvaturas da Coluna Vertebral/complicações , Curvaturas da Coluna Vertebral/etiologia , Glutamato Descarboxilase/imunologia , Atrofia Muscular Espinal/diagnóstico , Atrofia Muscular Espinal/complicações , Atrofia Muscular Espinal/imunologia , Autoanticorpos/sangue , Autoanticorpos/imunologia , Imunoglobulinas Intravenosas/uso terapêutico , Adulto , Rigidez Muscular/imunologia , Rigidez Muscular/tratamento farmacológico , Rigidez Muscular/diagnóstico , Eletromiografia , Imageamento por Ressonância MagnéticaRESUMO
BACKGROUND: Glycine receptor antibodies (GlyR-ab) were reported in a patient with progressive encephalomyelitis with rigidity and myoclonus (PERM). METHODS: Three additional patients were clinically described. GlyR-ab was detected with a cell-based assay of HEK293 cells transfected with the α1 subunit of the GyR. RESULTS: A 33-year-old woman presented with diplopia, dysphagia and gait ataxia that improved in 5 weeks. Then, she developed a typical stiff-person syndrome (SPS) that resolved with corticosteroids, but relapsed 17 months later with a stiff limb syndrome. After treatment with intravenous immunoglobulins (IVIG), she has been asymptomatic for 8 years. A 60-year-old man developed, dysphagia, diplopia, left facial palsy and right trigeminal hypoaesthesia in a few days, followed by muscular rigidity, corticospinal signs, myoclonic jerks and severe dysautonomia. He developed seizures and suffered a cardiac arrest that left him in a persistent vegetative state. A 48-year-old man presented with leg rigidity and frequent spells of trismus, muscle spasms followed by opisthotonus and diaphoresis. The symptoms were antedated by pruritus of the left scapulae, right arm and T11-T12 dermatome. At the same time he became progressively more aggressive with emotional irritability. He also developed dysgeusia (metallic taste) and severe concurrent behavioural changes and diurnal hypersomnia. Only the rigidity and the spasms improved after therapy. CONCLUSIONS: The clinical picture associated with GlyR-ab is wider than the classical view of PERM. GlyR-ab should be examined in patients with core symptoms of muscle rigidity and spasms atypical for SPS.
Assuntos
Encefalomielite/imunologia , Rigidez Muscular/imunologia , Receptores de Glicina/imunologia , Adulto , Anticorpos/sangue , Encefalomielite/complicações , Feminino , Células HEK293 , Humanos , Masculino , Pessoa de Meia-Idade , Rigidez Muscular/complicações , Mioclonia/complicações , Mioclonia/imunologiaRESUMO
INTRODUCTION: Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare disorder. However, the outcome is still variable with different serological and tumor associations, and the elements to good response with less relapse is yet to be elucidated. METHOD: We present a case and obtain a literature review of patients with PERM and make comparisons based on different serological groups. We also analyze patients with idiopathic PERM that had detailed medical records. RESULTS: 81 patients were collected and analyzed. The largest group were glycine receptor-antibody (GlyR-Ab)-positive (70%), and the seropositive-GlyR-Ab-negative group had better response to immunotherapy. Malignancy can occur up to 2 years from the presentation of PERM. Among the 18 cases with detailed records, the patients who had good outcome initiate immunotherapy within 2 months from presentation. 9 of the 12 patients who experienced no relapse had non-steroid immunotherapy. The maximal interval time of relapse was 24 months. CONCLUSION: We recommend tumor surveillance up to 2 years in patients with PERM and early administration of immunotherapies and maintain with non-steroid immunotherapy with or without oral corticosteroid for a minimum of 2 years to reduce the risk of relapse in GlyR-Ab-positive patients.
Assuntos
Autoanticorpos , Encefalomielite/diagnóstico , Rigidez Muscular/diagnóstico , Receptores de Glicina/imunologia , Encefalomielite/imunologia , Feminino , Humanos , Pessoa de Meia-Idade , Rigidez Muscular/imunologiaAssuntos
Rigidez Muscular Espasmódica , Autoanticorpos/imunologia , Encefalomielite/diagnóstico , Encefalomielite/imunologia , Encefalomielite/terapia , Humanos , Imunoterapia , Rigidez Muscular/diagnóstico , Rigidez Muscular/imunologia , Rigidez Muscular/terapia , Neoplasias/complicações , Prognóstico , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/terapiaRESUMO
We present a case of a 65-year-old African American male, immunosuppressed on Tacrolimus, who initially presented with cerebellar ataxia and rapidly developed Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) with positive anti-glutamic acid decarboxylase (GAD65) antibodies, no underlying malignancy, and normal neuroimaging. PERM is a rare spectrum of Stiff Person Syndrome (SPS), which is strongly associated with anti-GAD antibodies and characterized by flare-ups and remissions of encephalopathy, myelopathy and rigidity with myoclonus. PERM is diagnosed clinically and has been successfully treated with both Intravenous Immunoglobulin (IVIg) and plasmapheresis. Our patient was successfully treated with IVIg. On day 14 after starting IVIg treatment, his neurological symptoms started to improve and ultimately returned to baseline.
Assuntos
Autoanticorpos/imunologia , Autoantígenos/imunologia , Doenças Autoimunes do Sistema Nervoso/etiologia , Ataxia Cerebelar/complicações , Encefalomielite/etiologia , Glutamato Descarboxilase/imunologia , Imunoglobulinas Intravenosas/uso terapêutico , Rigidez Muscular/etiologia , Rigidez Muscular Espasmódica/etiologia , Idoso , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Autoimunes do Sistema Nervoso/terapia , Ataxia Cerebelar/imunologia , Encefalomielite/imunologia , Encefalomielite/terapia , Humanos , Hospedeiro Imunocomprometido , Imunoterapia , Transplante de Rim , Masculino , Rigidez Muscular/imunologia , Rigidez Muscular/terapia , Plasmaferese , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/imunologia , Complicações Pós-Operatórias/terapia , Indução de Remissão , Rigidez Muscular Espasmódica/imunologia , Rigidez Muscular Espasmódica/terapiaRESUMO
BACKGROUND: Antibody-associated disorders of the central nervous system are increasingly recognised in adults and children. Some are known to be paraneoplastic, whereas in others an infective trigger is postulated. They include disorders associated with antibodies to N-methyl-d-aspartate receptor (NMDAR), voltage-gated potassium channel-complexes (VGKC-complex), GABAB receptor or glycine receptor (GlyR). With antibodies to NMDAR or VGKC-complexes, distinct clinical patterns are well characterised, but as more antibodies are discovered, the spectra of associated disorders are evolving. GlyR antibodies have been detected in patients with progressive encephalopathy with rigidity and myoclonus (PERM), or stiff man syndrome, both rare but disabling conditions. CASE REPORT: We report a case of a young child with focal seizures and progressive dyskinesia in whom GlyR antibodies were detected. Anticonvulsants and immunotherapy were effective in treating both the seizures and movement disorder with good neurological outcome and with a decline in the patient's serum GlyR-Ab titres. CONCLUSION: Glycine receptor antibodies are associated with focal status epilepticus and seizures, encephalopathy and progressive dyskinesia and should be evaluated in autoimmune encephalitis.
Assuntos
Discinesias/tratamento farmacológico , Discinesias/imunologia , Receptores de Glicina/imunologia , Estado Epiléptico/tratamento farmacológico , Estado Epiléptico/imunologia , Anticonvulsivantes/uso terapêutico , Autoanticorpos/sangue , Pré-Escolar , Discinesias/complicações , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Masculino , Metilprednisolona/uso terapêutico , Rigidez Muscular/complicações , Rigidez Muscular/tratamento farmacológico , Rigidez Muscular/imunologia , Mioclonia/complicações , Mioclonia/tratamento farmacológico , Mioclonia/imunologia , Fenótipo , Estado Epiléptico/complicaçõesAssuntos
Doenças Autoimunes do Sistema Nervoso/tratamento farmacológico , Benserazida/farmacologia , Dopaminérgicos/farmacologia , Encefalomielite/tratamento farmacológico , Levodopa/farmacologia , Rigidez Muscular/tratamento farmacológico , Mioclonia/tratamento farmacológico , Receptores de Glicina/imunologia , Adulto , Autoanticorpos , Doenças Autoimunes do Sistema Nervoso/imunologia , Doenças Autoimunes do Sistema Nervoso/fisiopatologia , Benserazida/administração & dosagem , Dopaminérgicos/administração & dosagem , Combinação de Medicamentos , Encefalomielite/imunologia , Encefalomielite/fisiopatologia , Humanos , Levodopa/administração & dosagem , Masculino , Rigidez Muscular/imunologia , Rigidez Muscular/fisiopatologia , Mioclonia/imunologia , Mioclonia/fisiopatologiaRESUMO
A 62-year-old woman with one-year history of type 1 diabetes mellitus was admitted to our hospital with progressive weakness in the lower extremities and urinary dysfunction following high fever. On admission, she had rigidity and myoclonus in the upper extremities with sensory ataxia. Cerebrospinal fluid examination revealed mild pleocytosis and oligoclonal band. Glutamic acid decarboxylase (GAD) antibodies were detected at high titer in serum, but antibodies to glycine receptor (GlyR), thyroid peroxidase, mitochondrial M2, and GM1 were also detected. She was diagnosed with progressive encephalomyelitis with rigidity and myoclonus (PERM), which probably developed on the basis of polyglandular autoimmune syndromes. The clinical symptoms began to improve after initiation of intravenous high-dose methylprednisolone. Muscle weakness might be related to GM1 antibodies. This is the first report of PERM, in which GM1 antibodies were detected with GAD and GlyR antibodies.
Assuntos
Autoanticorpos/sangue , Encefalomielite/etiologia , Encefalomielite/imunologia , Gangliosídeo G(M1)/imunologia , Glutamato Descarboxilase/imunologia , Rigidez Muscular/etiologia , Rigidez Muscular/imunologia , Mioclonia/etiologia , Poliendocrinopatias Autoimunes/complicações , Poliendocrinopatias Autoimunes/imunologia , Receptores de Glicina/imunologia , Biomarcadores/sangue , Encefalomielite/diagnóstico , Feminino , Humanos , Pessoa de Meia-Idade , Rigidez Muscular/diagnóstico , Poliendocrinopatias Autoimunes/diagnósticoRESUMO
A 57-year-old woman without a known neoplasia developed opsoclonus, myoclonus, and ataxia. Positive anti-Ri antibodies were present in both serum and CSF. The patient also had progressive encephalomyelitis with rigidity, an association not previously described.